Immunohistochemistry frequently identifies SFT through positive staining for Vimentin, CD34, Bcl-2, and CD99, with CD34 serving as a critical marker to differentiate SFT from other spindle cell tumors. The gene discussed is BCL2; the disease is spindle cell neoplasm.